Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans

J Infect Dis. 1999 Oct;180(4):987-91. doi: 10.1086/314973.


To determine whether there was a correlation between the kinetics or frequency of antibody to mammalian-derived hepatitis C virus (HCV) second envelope protein (E2) and development of chronicity or self-limitation of HCV infections, serial sera were examined for anti-E2, anti-HCV with confirmation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse transcriptase-polymerase chain reaction (RT-PCR) from 6 cases of self-limited infection and 6 cases of chronic infection in chimpanzees, and from 5 cases of self-limited infection and 3 cases of chronic infection in patients. Anti-E2 developed earlier, more frequently, and to higher titer in chimpanzees and patients who were developing chronic infection than in those with self-limited infections. Thus anti-E2 is unlikely to play a role in self-limitation of the infection. However, long-term persistence of anti-E2 correlates with chronic infection. There was little or no correlation between the timing of development of anti-E2 and anti-HCV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Transfusion
  • Follow-Up Studies
  • Hepacivirus / immunology*
  • Hepatitis C Antibodies / blood*
  • Hepatitis C, Chronic / immunology*
  • Hepatitis C, Chronic / physiopathology
  • Humans
  • Pan troglodytes
  • Prospective Studies
  • Time Factors
  • Viral Envelope Proteins / immunology*


  • Hepatitis C Antibodies
  • Viral Envelope Proteins
  • glycoprotein E2, Hepatitis C virus